Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes

Ronnie Aronson, Peter A. Gottlieb, Jens S. Christiansen, Thomas W. Donner, Emanuele Bosi, Bruce W. Bode, Paolo Pozzilli

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Fingerprint

Dive into the research topics of 'Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes'. Together they form a unique fingerprint.

Medicine & Life Sciences